Allurion Technologies, Inc. - ALUR STOCK NEWS

Welcome to our dedicated page for Allurion Technologies news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on Allurion Technologies stock.

Allurion Technologies, Inc. (NYSE: ALUR) is a pioneering medical device company committed to combating obesity through innovation. The company offers a comprehensive weight loss platform known as the Allurion Program, which includes the world's first and only swallowable, procedure-less intragastric balloon designed for weight loss. This unique solution, the Allurion Balloon, is delivered without the need for surgery, endoscopy, or anesthesia, making it a convenient and less invasive option for patients.

The Allurion Program is further enhanced by the Allurion Virtual Care Suite (VCS), a suite of AI-powered tools that aid in remote patient monitoring, proprietary behavior change programs, secure messaging, and video telehealth services. The virtual suite also includes the Allurion Mobile App for consumers, the Allurion Connected Scale, and Allurion Insights for healthcare providers featuring the Iris AI Platform. These components work synergistically to ensure a comprehensive and personalized weight loss journey for patients.

Recent achievements by Allurion include a significant partnership with the Somerset NHS Foundation Trust, making it the first NHS trust to introduce the Allurion Gastric Balloon. This partnership aims to provide rapid, effective weight loss solutions to those most in need, particularly patients with high BMIs who require rapid weight loss to qualify for lifesaving surgeries.

Clinical data supports the efficacy and safety of the Allurion Program, with studies showing an average weight loss of 10-15% of body weight over approximately four months. Impressively, around 96% of this weight loss can be sustained one year after the balloon passes. The program has demonstrated particular effectiveness in patients with higher BMIs, with weight loss percentages reaching up to 20% over six months for those with a BMI over 40.

Financially, Allurion has shown robust growth and potential, evidenced by a 30% increase in procedural volume, reflecting strong demand for their innovative solutions. The company's commitment to expanding its offerings and its strategic partnerships aims to address the growing obesity epidemic, which imposes significant financial burdens on healthcare systems worldwide.

Allurion's leadership team, led by Founder and CEO Dr. Shantanu Gaur, continues to drive the company forward with a clear vision and strategic direction, focusing on expanding their global footprint and enhancing patient outcomes through continuous innovation and partnerships.

05/02/2024 08:00 AM

News

Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey

Rhea-AI Summary

Allurion Technologies, Inc. (NYSE: ALUR) announced three scientific presentations at IFSO-European Chapter 2024, highlighting 80% sustained weight loss at three years with the Allurion Program and successful outcomes of an AI-powered conversational agent for obesity treatment. The data showcased positive long-term weight maintenance results and patients' healthier eating habits post-program. Additionally, the innovative AI-powered weight loss coach, Coach Iris, received positive feedback for its personalized, trustworthy, and empathetic approach.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.38%

Tags

04/30/2024 08:30 AM

News

Allurion Announces Preliminary First Quarter 2024 Results

Rhea-AI Summary

Allurion Technologies, Inc. announced preliminary first quarter 2024 results, with quarter-over-quarter revenue growth, procedural volume growth, and a significant decrease in cash burn. The company expects revenue between $9.2 million to $9.3 million, 12%-13% higher than the fourth quarter of 2023, procedural volume growth of 22%, and reduced cash burn of $8 million to $9 million. Allurion remains optimistic about future growth and business opportunities.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/17/2024 08:31 AM

News

Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Rhea-AI Summary

Allurion Technologies, Inc. (NYSE: ALUR) closes a $48 million convertible senior secured note financing with RTW Investments, reducing interest expenses, extending cash runway, and strengthening the partnership. The transaction simplifies the capital structure, lowers the interest rate to 6%, and extends the maturity of the debt. The funding will be used to repay existing term loans, providing operational flexibility and enhancing future prospects.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.05%

Tags

04/04/2024 08:00 AM

News

Allurion Expands Virtual Care Suite to the United States

Rhea-AI Summary

Allurion Technologies, Inc. (ALUR) announces the commercial availability of its Virtual Care Suite (VCS) in the United States, a comprehensive weight-loss management suite powered by AI. The VCS aims to enhance patient outcomes and satisfaction through remote patient monitoring, telehealth, and care team collaboration. The addition of Coach Iris, a 24/7 AI-powered weight loss coach, further personalizes the behavior change program. The VCS has shown to improve patient results, engagement, and satisfaction, with clinics experiencing an additional 11% weight loss and a 17% increase in Net Promoter Score (NPS). Allurion will showcase the VCS at the Obesity Medicine Conference in Denver on April 25, introducing a new version of Allurion Insights, the web-based dashboard for providers.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

78.03%

Tags

03/21/2024 08:00 AM

News

Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Rhea-AI Summary

Allurion Technologies, Inc. (ALUR) reported Q4 revenue of $8.2 million and full-year 2023 revenue of $53.5 million, reiterating 2024 guidance. The company completed enrollment in the AUDACITY pivotal trial ahead of schedule, conducted research on healthcare professionals and patients, and treated the first UK NHS-reimbursed patients with the Allurion Balloon. Despite macroeconomic challenges, Allurion saw a 30% increase in procedural volume. The company expects 2024 revenue of $60-65 million, gross margins of 77-79%, and a cash burn of $30 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.29%

Tags

03/13/2024 08:30 AM

News

Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Rhea-AI Summary

Allurion Technologies, Inc. (ALUR) will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on March 12 - 13, 2024. The company's CEO and CFO will present at the event, with a live webcast available on their website.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.04%

Tags

03/04/2024 08:30 AM

News

Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024

Rhea-AI Summary

Allurion Technologies, Inc. (ALUR) will report Q4 2023 financial results on March 21, 2024. A conference call will follow to discuss results and provide a business update.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.31%

Tags

02/20/2024 04:05 PM

News

Allurion to Participate in Cowen’s 44th Annual Health Care Conference

Rhea-AI Summary

Allurion Technologies, Inc. (ALUR) to participate in the 44th Annual Cowen Health Care Conference. CEO and CFO to present on March 5, 2024, at 9:50 a.m. Eastern Time.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.66%

Tags

02/08/2024 08:30 AM

News

Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Rhea-AI Summary

Allurion Technologies, Inc. (ALUR) will be participating in the BTIG Snowbird Conference from February 12-14, 2024. CEO Shantanu Gaur and CFO Chris Geberth will be available for investor 1x1 meetings.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1%

Tags

01/29/2024 08:00 AM

News

Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies

Rhea-AI Summary

Allurion Technologies, Inc. (NYSE:ALUR) has appointed Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan brings 20 years of experience as a legal and compliance officer at public companies, with his most recent role at Acushnet Company. In this new role, Brendan will lead the company’s legal and compliance strategies, guiding its global expansion and commitment to delivering safe and effective weight loss solutions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.1%

Tags

FAQ

What is the current stock price of Allurion Technologies (ALUR)?

The current stock price of Allurion Technologies (ALUR) is $3.7 as of January 23, 2025.

What is the market cap of Allurion Technologies (ALUR)?

The market cap of Allurion Technologies (ALUR) is approximately 10.8M.

What is the Allurion Program?

The Allurion Program is a comprehensive weight loss platform that includes the Allurion Gastric Balloon, the world's first swallowable, procedure-less gastric balloon, and the Allurion Virtual Care Suite featuring AI-powered tools for remote patient monitoring and behavior management.

How does the Allurion Gastric Balloon work?

The Allurion Gastric Balloon is a swallowable capsule that, once ingested, is filled and remains in the stomach for approximately four months, creating a feeling of fullness and helping patients lose 10-15% of their body weight on average.

What makes the Allurion Program unique?

The Allurion Program is unique because it combines a non-invasive gastric balloon with a suite of digital health tools, providing a comprehensive approach to weight loss that includes behavior modification, remote monitoring, and personalized support.

Is the Allurion Balloon safe?

Yes, the Allurion Balloon is supported by over 30 peer-reviewed studies indicating it is a safe and effective method for weight loss. It does not require surgery, endoscopy, or anesthesia.

Who can benefit from the Allurion Program?

The Allurion Program is particularly beneficial for individuals with a higher BMI (Body Mass Index) who are seeking a rapid, non-surgical weight loss solution to improve their health and qualify for further medical treatments.

What recent achievements has Allurion accomplished?

Allurion recently partnered with the Somerset NHS Foundation Trust, the first NHS trust to introduce the Allurion Gastric Balloon, aiming to provide effective weight loss solutions quickly and efficiently.

What are the components of the Allurion Virtual Care Suite?

The Allurion Virtual Care Suite includes the Allurion Mobile App, Allurion Insights for healthcare providers, the Iris AI Platform, and the Allurion Connected Scale, all designed to support and monitor patients' weight loss journeys remotely.

How effective is the Allurion Program?

Studies show that the Allurion Program helps patients lose an average of 10-15% of their body weight in four months, with around 96% of this weight loss sustained one year after the balloon passes.

What support does Allurion offer to healthcare providers?

Allurion provides healthcare providers with access to Allurion Insights, the Iris AI Platform, and comprehensive support tools through the Virtual Care Suite to customize and monitor weight loss therapy for their patients.

What is the financial outlook for Allurion?

Allurion has shown strong growth in procedural volume and revenue, reflecting increasing demand for their solutions. They are strategically expanding their global presence and enhancing patient outcomes through ongoing innovation and partnerships.